- Autor
-
Pracoviště
AbbVie Inc North Chicago IL USA 1 CREATE Centre Cardiff University Card... 1 Center for Arthritis Research Conway ... 1 Charité Universitätsmedizin Berlin Be... 1 College of Medical Veterinary and Lif... 1 Columbia University New York NY USA 1 Department of Rheumatology 1st Facult... 1 Division of Rheumatology David Geffen... 1 Institute of Rheumatology Na Slupi 4 ... 1 University of California 1000 Veteran... 1 University of California Davis Sacram... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
-
Pracoviště
AbbVie Inc North Chicago IL USA 1 CREATE Centre Cardiff University Card... 1 Center for Arthritis Research Conway ... 1 Charité Universitätsmedizin Berlin Be... 1 College of Medical Veterinary and Lif... 1 Columbia University New York NY USA 1 Department of Rheumatology 1st Facult... 1 Division of Rheumatology David Geffen... 1 Institute of Rheumatology Na Slupi 4 ... 1 University of California 1000 Veteran... 1 University of California Davis Sacram... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
NLK
Directory of Open Access Journals
od 2014
PubMed Central
od 2014
Europe PubMed Central
od 2014
ProQuest Central
od 2014-12-01
Open Access Digital Library
od 2014-01-01
Open Access Digital Library
od 2014-01-01
Nursing & Allied Health Database (ProQuest)
od 2014-12-01
Health & Medicine (ProQuest)
od 2014-12-01
Public Health Database (ProQuest)
od 2014-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2014
Springer Journals Complete - Open Access
od 2014-12-01
Springer Nature OA/Free Journals
od 2014-12-01
PubMed
38180720
DOI
10.1007/s40744-023-00624-3
Knihovny.cz E-zdroje
INTRODUCTION: Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical trials. METHODS: Pooled data from six randomized trials in the SELECT phase 3 program were included. Key laboratory parameters and safety data were measured for UPA 15 and 30 mg once daily (QD), adalimumab (ADA) 40 mg every other week + methotrexate (MTX), and MTX monotherapy. Exposure-adjusted event rates (EAERs) of adverse events were calculated. RESULTS: A total of 3209 patients receiving UPA 15 mg QD (10 782.7 patient-years [PY]), 1204 patients receiving UPA 30 mg QD (3162.5 PY), 579 patients receiving ADA + MTX (1573.2 PY), and 314 patients receiving MTX monotherapy (865.1 PY) were included, representing up to 6.5 years of total exposure. Decreases in mean levels of hemoglobin, neutrophils, and lymphocytes, and increases in mean levels of liver enzymes and creatinine phosphokinase were observed with UPA, with grade 3 or 4 changes observed in some patients. Mean low- and high-density lipoprotein cholesterol ratios remained stable for patients receiving UPA 15 mg QD. EAERs of anemia and neutropenia occurred at generally consistent rates between UPA and active comparators (3.1-4.3 and 1.7-5.0 events [E]/100 PY across treatment groups, respectively). Rates of hepatic disorder were higher with MTX monotherapy, UPA 15 mg and UPA 30 mg (10.8, 9.7, and 11.0 E/100 PY, respectively) versus ADA + MTX (6.4 E/100 PY). Rates of lymphopenia were highest with MTX monotherapy (3.2 E/100 PY). Treatment discontinuations due to laboratory-related events were rare, occurring in 1.1% and 2.2% of patients treated with UPA 15 and 30 mg QD, respectively. CONCLUSIONS: The results of this integrated long-term analysis of laboratory parameters continue to support an acceptable safety profile of UPA 15 mg QD for moderate-to-severe RA.
- Publikační typ
- časopisecké články MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.